Emrosi Officially Launched for Treatment of Inflammatory Rosacea

Journey Medical has announced the launch and initial prescriptions for Emrosi for the treatment inflammatory lesions of rosacea in adults.

According to a press release from the manufacturer, the minocycline hydrochloride modified-release capsule (40 mg) designed to treat inflammatory lesions of rosacea in adults is now available by prescription is coming to specialty pharmacy chains. 

Approved by the FDA in November 2024, Emrosi combines 10 mg immediate-release and 30 mg extended-release minocycline, providing the lowest-dose oral minocycline available for rosacea treatment.  Clinical trial data indicates the therapy is associated with superior outcomes compared to Oracea and to placebo while maintaining a similar safety profile, the manufacturer said.

“We are thrilled that the initial distribution to pharmacies is ongoing and the first Emrosi prescriptions have been filled," Claude Maraoui, CEO of Journey Medical, said in the news release. "The launch of Emrosi marks a major milestone for Journey Medical and underscores our commitment to improving the quality of life for those living with dermatology conditions such as rosacea.”

Source: Journey Medical press release. March 24, 2025.